CurrentUnitedHealthcarePolicy CS079ID.B

Minimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Idaho Only)

State-specific UnitedHealthcare medical policy for Idaho (including Idaho Medicaid Plus) describing coverage positions and medical necessity criteria for minimally invasive procedures treating GERD, gastroparesis, achalasia, diffuse esophageal spasm, and related interventions (GES, pyloroplasty, POEM, endoscopic GERD therapies, LINX, etc.).

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Idaho Only)

Policy CodePolicy CS079ID.B

Change TypeTitle revisioncoverage rationale and coverage statements added/updatedcodes added

Effective DateJun 1, 2026

Next Review Date

Key ActionProvide complete, legible medical record documentation that supports medical necessity, verify Idaho-specific applicability and prior authorization requirements, and document prior conservative therapy failure and informed consent regarding evidence limitations.

SourceLink

POLICY UPDATE CHANGES

Title changed on 2026-06-01 from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Idaho Only)'

Coverage Rationale language was added (partial line in document: 'Summary of Changes = Coverage Rationale Added language to indica')

Title changed from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Idaho Only)' to a new title (summary indicates title change).

GES therapy and surgical pyloroplasty were added as proven and medically necessary for refractory gastroparesis and chronic intractable nausea/vomiting of diabetic or idiopathic etiology.

Language indicating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing Achalasia was removed.

Specifies types of documentation and that documentation does not guarantee coverage.

Added CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 to Applicable Codes.

Updated definition of 'Gastroparesis'.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

3Therapies stated as proven/medically necessary (GES, pyloroplasty, POEM for achalasia/ DES)

5Procedures listed as unproven/not medically necessary

16CPT codes referenced in this part

70%Approx. 1-year clinical success G-POEM (Mandarino 2024)

87%WPR success POEM for all spastic esophageal disorders (SEDs)

Coverage Summary

This state-specific UnitedHealthcare policy (Idaho, including Idaho Medicaid Plus) defines coverage positions and medical necessity criteria for minimally invasive upper gastrointestinal procedures addressing GERD, gastroparesis, achalasia, diffuse esophageal spasm, and related interventions (such as GES, pyloroplasty, POEM, G-POEM, endoscopic GERD therapies, and LINX). The policy includes coverage rationale, definitions, evidence summaries, and applicable CPT procedure codes.

Coverage stance is mixed: certain therapies are designated as proven and medically necessary when specific clinical criteria are met (for example, GES and surgical pyloroplasty for refractory gastroparesis; POEM for achalasia and diffuse esophageal spasm), while multiple endoscopic GERD interventions, G-POEM, and other indications of POEM are described as unproven and not medically necessary due to insufficient evidence. The policy is effective 2026-06-01 and its status is CURRENT.

Policy Identifiers

policy_numberCS079ID.B

subjectMinimally invasive procedures for upper gastrointestinal diseases (Idaho)

geographic_scopeIdaho (includes Idaho Medicaid Plus)

effective_date2026-06-01

statusCURRENT

Medical Necessity / Coverage Criteria

Covered / Medically Necessary

Covered when ALL of the following criteria are met:

ALL of the following

Gastric electrical stimulation (GES) is indicated for refractory Gastroparesis or chronic intractable (drug-refractory) nausea and vomiting secondary to Gastroparesis of diabetic or idiopathic etiology. Documentation must include prior conservative therapies tried and objective evidence of delayed gastric emptying (e.g., gastric emptying scintigraphy).
Surgical pyloroplasty (open or laparoscopic) is indicated for refractory Gastroparesis or chronic intractable (drug-refractory) nausea and vomiting secondary to Gastroparesis of diabetic or idiopathic etiology. Documentation must include prior conservative therapies tried and objective evidence of delayed gastric emptying when available.
Per oral endoscopic myotomy (POEM) is indicated for individuals with Achalasia or Diffuse Esophageal Spasm. Documentation must include diagnostic confirmation (e.g., high-resolution esophageal manometry) and prior management steps as appropriate.

Provider Actions & Documentation Requirements

Documentation Required

Medical record documentation

The patient’s medical record must include clear documentation supporting medical necessity, including history, prior therapies, exam findings, and diagnostic test results; records must be legible and available on request.

History of present illness and relevant past medical history (including etiology of gastroparesis or GERD and symptom duration/severity).
Physical examination findings pertinent to the condition.
Objective diagnostic test results (e.g., gastric emptying scintigraphy, esophageal manometry, endoscopy reports, imaging) with dates and values.
Documentation of prior conservative and medical therapies tried, duration, doses, and reason for discontinuation or failure.
Evidence of specialist evaluation (e.g., gastroenterologist, surgeon) when applicable.
Notes, operative reports, and device implant details when performed (including device model/serial when applicable).
Records must be legible, maintained in the patient chart, and made available upon request for review.

Coding — Referenced and Applicable Codes

Referenced CPT procedure codes (for clinician/billing reference)CPT

43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed.
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease.
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (i.e., magnetic band), including cruroplasty when performed.
43289	Unlisted laparoscopy procedure, esophagus.
43497	Lower esophageal myotomy, transoral (i.e., peroral endoscopic myotomy [POEM]).
43499	Unlisted procedure, esophagus.
43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43659	Unlisted laparoscopy procedure, stomach.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.

1–10 of 14

1/2

FDA PMA/510(k)/HDE devices referencedmixed

P100049	LINX Reflux Management System PMA number (Torax Medical)
K233240	GERDx-System 510(k) Number K233240 (510(k) Premarket Notification received May 24, 2024)
K071651	Bard EndoCinch Endoscopic Suturing System approval summary (FDA document)
K071553	NDO Surgical Endoscopic Plication System approval (FDA document)
K143634	Medigus Ultrasound Surgical Endostapler (MUSE) 510(k) approval K143634
P980053	Durasphere PMA number (approved for urology; off-label for esophageal use)

Applicable CPT codes (added / covered per policy)CPTCovered

43647
43648
43659
43881
43882
64590
64595

Background & Evidence Summary

This policy references major professional guidance and evidence assessments including ACG, AGA, ASGE/SAGES position statements and guidelines, NICE interventional guidance, and HTAs/systematic reviews (e.g., Hayes, ECRI). These sources evaluate procedures such as GES, pyloroplasty, POEM, G-POEM, TIF/EsophyX, MUSE, Stretta, endoscopic plication/suturing, and LINX with varying conclusions.

Across guidance and HTA reports the quality of evidence is variable: some societies provide conditional or expert-based recommendations supporting procedures in selected patients (for example POEM for achalasia, pyloroplasty for refractory gastroparesis, consideration of GES as an HDE option), while HTAs and ECRI frequently characterize the overall evidence for many endoscopic GERD and newer gastroparesis interventions as low or very low quality, calling for larger RCTs and longer-term outcome data and thus issuing cautious or conditional recommendations.

Study/Source	Finding/Note
Werner et al. 2019 (RCT POEM vs LHM+fundoplication)	2-year clinical success: POEM 83.0% vs LHM 81.7%; POEM non-inferior (noted higher post‑procedure reflux).
Martinek et al. 2022 (G-POEM randomized sham‑controlled)	At 6 months: clinical success 15/21 G-POEM vs 4/20 sham; 10 serious adverse events (3 related to G‑POEM).
Zerbib et al. 2020 (Stretta RCT, double‑blind sham)	No significant difference vs sham at 24 and 48 weeks for symptoms or PPI use; did not demonstrate efficacy over sham.
Enterra Therapy System (FDA HDE, 2000)	HDE approved for chronic intractable (drug‑refractory) nausea and vomiting secondary to diabetic or idiopathic gastroparesis in ages 18–70; labeling lists contraindications.
ECRI assessments (GES, G‑POEM, Stretta, LINX, EsophyX)	Conclude potential benefits but very low/insufficient quality evidence; call for larger RCTs and longer‑term outcomes (updated reviews noted).
ACG guideline Katz 2021 (GERD) and ACG gastroparesis guidance	Recommend consideration of MSA as alternative to fundoplication for regurgitation; ACG suggests GES may be considered as HUD for refractory diabetic/idiopathic gastroparesis (conditional, low quality).
MSA/LINX systematic reviews and RCTs (e.g., Bell 2019/2020, Fadel 2024, Valinoti 2024)	Multiple studies show symptom control, high PPI cessation rates and patient satisfaction; complications include dysphagia, dilation, and device explantation/erosion; long‑term comparative data limited.
Mandarino 2024 (G‑POEM systematic review/meta‑analysis)	Pooled ~70% clinical success at 1 year (n=952); evidence weak with variable definitions and limited long‑term data.
Stojilkovic et al. 2023 / other G‑POEM series (safety/long‑term)	Observational series report sustained symptom improvement in many patients but heterogeneity, inconsistent definitions, and limited long‑term durability data.
Kalapala et al. 2022 (EFTP RCT)	65.7% achieved ≥50% GERD‑HRQL improvement vs 2.9% sham at 12 months; suggests benefit for endoscopic full‑thickness fundoplication in selected patients.
POEM systematic reviews/meta‑analyses (e.g., Khan 2017, North & Tewari 2024)	High clinical success for achalasia and spastic esophageal disorders (WPR ≈ 87% overall); POEM considered effective and non‑inferior to LHM in RCTs but with higher reflux risk.
Mandarino / Stojilkovic / Martinek group evidence summarized (G‑POEM)	RCT evidence limited but some RCT shows superiority to sham; overall evidence judged insufficient/very low quality and further RCTs needed.
Selected G‑POEM safety series (Baret 2022, Chung 2022)	Procedure generally safe in experienced centers; reported adverse events include bleeding, mucosal injury, abscess, dumping; serious AE rates low but present.
Hayes HTA and other HTAs on GES and Stretta	Hayes concluded GES effectiveness uncertain with low‑quality evidence and device removal rates 7–12%; Stretta HTA found low‑quality evidence with potential but unproven benefit.
GERDx/MUSE and other endoscopic GERD device summaries (FDA clearances noted)	Various devices received FDA 510(k)/PMA (EsophyX, MUSE, GERDx submitted 510(k)), studies show short‑term symptom/QOL improvements but durability and comparative effectiveness remain uncertain.

Key definitions used in the policy: Achalasia — a primary esophageal motor disorder with impaired EGJ relaxation and loss of organized peristalsis; Diffuse Esophageal Spasm — rare motility disorder with simultaneous/uncoordinated contractions and dysphagia; Gastroesophageal Reflux Disease (GERD) — condition from LES dysfunction allowing reflux; Gastroparesis — delayed gastric emptying with objective evidence required for diagnosis.

Procedural/technology terms defined include: POEM (peroral endoscopic myotomy) for achalasia and spastic esophageal disorders; Z-POEM (Zenker's POEM) for Zenker's diverticulum; G-POEM (gastric POEM) for endoscopic pyloromyotomy in gastroparesis; GES (gastric electrical stimulation, e.g., Enterra Therapy System - FDA HDE for chronic intractable nausea/vomiting secondary to diabetic or idiopathic gastroparesis); Stretta (endoscopic radiofrequency for GERD); EFTP/TIF/MUSE (endoscopic full-thickness plication / transoral incisionless fundoplication / Medigus endostapler); and MSA/LINX (magnetic sphincter augmentation / LINX Reflux Management System).

Revision History

2026-06-01title_changeLatest

Policy title changed on 2026-06-01 from 'Minimally Invasive Procedures for Gastric and Esophageal Diseases (for Idaho Only)'.

2026-06-01coverage_rationale_addedLatest

Coverage Rationale language was added including: GES therapy is proven and medically necessary for refractory gastroparesis or chronic intractable nausea/vomiting of diabetic or idiopathic etiology; surgical pyloroplasty (open or laparoscopic) is proven and medically necessary for refractory gastroparesis; POEM is proven and medically necessary for Achalasia or Diffuse Esophageal Spasm; several procedures (G-POEM, endoscopic GERD therapies, injection/implantation techniques, LINX, GERDx) are identified as unproven/not medically necessary for GERD.

Policy Summary

PayerUnitedHealthcare

PolicyMinimally Invasive Procedures for the Treatment of Upper Gastrointestinal Diseases (for Idaho Only)

Policy CodePolicy CS079ID.B

Change TypeTitle revisioncoverage rationale and coverage statements added/updatedcodes added

Effective DateJun 1, 2026

Next Review Date

SourceLink

On This Page

Per oral endoscopic myotomy (POEM) is not covered for indications other than Achalasia or Diffuse Esophageal Spasm (e.g., Zenker’s diverticula).

Operational note: Coverage criteria are applied according to state- and plan-specific benefit design. Prior authorization and submission of supporting medical records/documentation are required. See Provider Actions for prior authorization and documentation instructions.

Not Medically Necessary / Unproven

The following are considered not medically necessary and unproven for the listed indications:

ANY of the following

Per oral endoscopic myotomy (POEM) for indications other than Achalasia or Diffuse Esophageal Spasm (e.g., Zenker’s diverticula) — insufficient evidence of efficacy.
Gastric per oral endoscopic myotomy (G-POEM) for the treatment of Gastroparesis — considered investigational/unproven and not medically necessary due to insufficient evidence of efficacy.
Endoscopic therapies for Gastroesophageal Reflux Disease (GERD) (including radiofrequency/ Stretta, endoscopic plication/suturing devices, transoral incisionless fundoplication [TIF]/EsophyX, MUSE, GERDx™) — unproven and not medically necessary for GERD due to insufficient evidence.
Injection or implantation techniques and other endoluminal procedures for GERD (including but not limited to bulking agents) — unproven and not medically necessary.
LINX Reflux Management System (magnetic sphincter augmentation) for GERD when considered unproven under this policy language — insufficient evidence for the stated indications in this policy context.

Prior Authorization

State-specific applicability / Prior Authorization

This policy applies to members in Idaho (including Idaho Medicaid Plus); providers must verify plan-specific prior authorization requirements and submit required documentation per the member’s benefit plan.

Applies to the state of Idaho, including Idaho Medicaid Plus plans.
Providers should confirm any additional prior authorization or benefit limits with the member’s specific UnitedHealthcare plan prior to scheduling.
Prior authorization requirements, where applicable, must be met and supporting records submitted at time of request.

Documentation Required

Document informed consent and prior conservative therapy

Document informed consent and prior conservative therapy attempts, including counseling that long-term benefits and risks may be uncertain for some procedures.

Record attempts and duration of prior conservative therapies (dietary changes, prokinetics, antiemetics, PPIs, weight-loss measures, behavioral therapy) and objective evidence of failure.
Document patient counseling regarding expected benefits, risks, alternatives, and the uncertain or limited long-term evidence for procedures such as G-POEM, certain endoscopic GERD therapies, and some device implants.
Obtain and document informed consent that reflects discussion of investigational or unproven status when applicable.

Note

Consider clinical trial enrollment for G-POEM

Discuss availability of clinical trials for procedures like G-POEM and novel interventions; document that the possibility of trial enrollment was reviewed with the patient and whether the patient was referred or declined.

Providers should consider and discuss clinical trial options for G-POEM and other investigational therapies when appropriate.
Document the discussion and any referrals; clinicaltrials.gov is a primary registry for identifying active trials.

Documentation Required

Enterra GES: FDA labeling and contraindications

Enterra gastric electrical stimulation is marketed under an HDE and has labeling contraindications that must be followed and documented when used.

Document that the use follows the FDA HDE/label restrictions for Enterra GES.
Key contraindications to note and document (per device labeling/brief): active infection at implant site, inability to tolerate anesthesia or surgery, conditions that contraindicate device implantation, and anatomical considerations that preclude safe placement.
Record that risks, benefits, and alternative treatments were discussed in the context of the device’s HDE status.

Prior Authorization

Coverage considerations tied to approvals & society guidance

Coverage decisions may depend on objective evidence of abnormal testing and documented failure of prior therapies in line with specialty society guidance and device approvals; ensure records demonstrate these requirements for procedures and devices noted below.

Coverage considerations often require objective diagnostic evidence (e.g., delayed gastric emptying scintigraphy for gastroparesis; manometry for achalasia) and documentation of failed conservative therapy.
Procedures/devices affected include: magnetic sphincter augmentation (MSA/LINX), transoral incisionless fundoplication (TIF/EsophyX), Per-oral Endoscopic Myotomy (POEM), Gastric POEM (G-POEM), and Gastric Electrical Stimulation (GES/Enterra).
Follow specialty society guidance and FDA approvals/HDE conditions when documenting medical necessity for these interventions.

Documentation Required

Operator credentialing / center experience

Document operator training and center experience for advanced endoscopic or device implantation procedures when required or recommended.

Include provider credentials, training in the specific procedure (e.g., POEM, G-POEM), procedural volume or case experience, and center-level capabilities for managing potential complications.
For novel or technically complex procedures, documentation of proctoring, specialized training, or participation in designated centers of excellence may be requested.

Documentation Required

Provide supporting medical records upon request

Provide supporting medical records upon request to substantiate medical necessity; records must be complete, legible, and available in a timely manner.

Examples of supporting documentation: office notes, specialist consultations, diagnostic test reports (scintigraphy, manometry, endoscopy), prior treatment records, operative reports, device implant logs, and informed consent forms.
Ensure records are maintained in the chart and can be produced promptly for utilization review or prior authorization audits.

language_relocated

Language was relocated from another Medical Policy into this policy's Coverage Rationale; specifically GES language was moved from the Gastrointestinal Disorders Diagnostic Procedures policy.

coverage_statement_added

GES therapy and surgical pyloroplasty added as proven and medically necessary for refractory gastroparesis and chronic intractable nausea/vomiting of diabetic or idiopathic etiology; POEM indicated as proven and medically necessary for Achalasia and Diffuse Esophageal Spasm; G-POEM and several endoscopic GERD therapies listed as unproven/not medically necessary.

removal_of_language

Language indicating functional lumen imaging probe technology is unproven and not medically necessary for diagnosing Achalasia was removed.

documentation_language_added

Medical records documentation language was added clarifying that benefit coverage is determined by federal/state/contractual requirements, documentation may be required to assess clinical criteria, and that medical records must fully support medical necessity and be made available upon request.

codes_added

CPT codes 43647, 43648, 43659, 43881, 43882, 64590, and 64595 were added to the Applicable Codes list.

definition_updated

Definition of 'Gastroparesis' was updated.